Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

C patients infected with HCV genotype 1 will be studied. If the results of the first three dosage cohorts indicate that more information would be desirable to more fully inform the design of a planned study of ITMN-191 in combination with Pegasys(R) and ribavirin, the Phase 1b study will be expanded to include additional cohorts of treatment-naive patients.

Further Details on Phase 1a Study -- Safety and Pharmacokinetic Profile of ITMN-191

The Phase 1a placebo-controlled study of ITMN-191 was completed in May of 2007, enrolling a total of 64 healthy volunteers. Doses in this study ranged from less than 10% to many-fold higher than those that will be evaluated in the three dosage cohorts of the Phase 1b trial. The study results show that:

-- ITMN-191 was well tolerated in all doses evaluated in Phase 1a study.

-- No Serious Adverse Events (SAEs) were reported and no subject

discontinued the study due to an Adverse Event (AE).

-- All AEs in subjects receiving ITMN-191 were classified as mild (CTCAE

Grade 1).

-- The most common AEs reported were gastrointestinal-related and

consisted of mild diarrhea and mild abdominal pain. These mild AEs

occurred predominantly in the highest dose group, a dose many-fold

higher than the doses planned in the Phase 1b study just begun.

-- No clinically significant laboratory abnormalities or changes in

electro-cardiograms were observed.

-- Food has a significant effect on the absorption of ITMN-191, with

higher AUC in patients who took ITMN-191 with a meal.

-- The pharmacokinetics of ITMN-191 were linear over the range of doses

planned in the Phase lb study.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IP
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... Oct. 20, 2014 Lpath, Inc. (NASDAQ: ... bioactive lipid-targeted therapeutics, received official notification from the European ... another key patent supporting its iSONEP™ and ASONEP™ ... European patent No. 2087002, claims compositions of matter ... two lead compounds, iSONEP and ASONEP. Sonepcizumab is ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... Company (Nasdaq: PRGO;TASE) today announced that Perrigo CFO Judy Brown ... 5, 2011 at 9:30 a.m. (IST) at the TASE Headquarters ... The day will include presentations on the Consumer Healthcare, ... and research and development. Perrigo Company is ...
... PARK, Calif., Oct. 4, 2011 CV Ingenuity, a ... a $16 million Series B round of financing led ... capital firm. Existing investors BioStar Ventures, Synergy Ventures and ... (CVI), which is focused on the development of a ...
Cached Medicine Technology:CV Ingenuity Announces Close of $16 Million Series B Financing Led by NEA 2
(Date:10/20/2014)... It’s hard to imagine what it’s like to live ... the world, it’s a reality. And while new shoes are ... to walk barefoot on rocky terrain or sewage-lined streets just ... friends. , Buckner International's Shoes for Orphan Souls ... October to encourage support for Air1 and while also providing ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... Dallas, Texas (PRWEB) October 20, 2014 ... therapeutic development for Partial Seizure, complete with comparative ... target, mechanism of action (MoA), route of administration ... and featured news and press releases. It also ... for Partial Seizure and special features on late-stage ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and related ... evening dresses . All the company’s old and new ... is up to 66 percent off. , SweetDressy.com ... field. Its dress specialists are striving to make more ... the world. All the company’s items are unique, graceful ...
(Date:10/19/2014)... causes inflammation in the spinal joints and was ... Egyptian royal families. Now a new study published ... of the American College of Rheumatology (ACR), refutes ... called diffuse idiopathic skeletal hyperostosis (DISH) in royal ... Dynasties. , Ankylosing spondylitis is a member ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... The National Alliance on Mental Illness (NAMI) reminds ... Health Awareness Month, a time for public education about serious ... 2008, the U.S. House of Representatives designated July as Bebe ... of the leading African American novelist and journalist, who also ...
... Va., July 1 Christian Children,s Fund, one ... now ChildFund International. The new name takes effect today. ... the organization,s new strategy to meet the needs of children ... and helps 15.2 million children and family members in 31 ...
... 21 criminal convictions secured , , INDIANAPOLIS, July 1 ... its Fraud and Abuse department, working with its ... 2008 as a result of its anti-fraud efforts. These efforts ... agencies. , , This announcement comes the day ...
... a micro-thin shield against acid attack -- , ... L. Moore, MD, wants women to know that their dental ... Crest and Oral-B Pro-Health products because they offer preventive solutions ... , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090701/NY38331 ...
... Inc. (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... webcast on Thursday, July 30, at 5:00 p.m. ET (23:00 CET) ... U.S. / Canada Dial-in Number: 866.272.9941, ... Code: 45596036, Replay Dial-in Number: 888.286.8010, ...
... Kids watching food commercials consumed 45 percent more snacks, study ... ads on TV leads to a boost in snacking among ... researchers say. , Yale University researchers conducted a series of ... One test found that children aged 7 to 11 who ...
Cached Medicine News:Health News:NAMI Observes Minority Mental Health Awareness Month 2Health News:Christian Children's Fund Name Change to ChildFund International Official 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 2Health News:WellPoint Recovers and Saves $75 Million Through Anti-Fraud Programs and Investigations in 2008 3Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 2Health News:Dr. Donnica Moore Advocates that Women Follow a Preventive Dental Health Routine that Includes Crest Pro-Health Enamel Shield 3Health News:BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET) 2Health News:TV Ads Trigger Mindless Eating 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: